This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
Dermatology and Therapy Open Access 25 May 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Anti-IL-17 mAbs herald new options in psoriasis. Nat Biotechnol 30, 475–476 (2012). https://doi.org/10.1038/nbt0612-475
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0612-475
This article is cited by
-
Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
Dermatology and Therapy (2016)
-
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
Oncogene (2015)
-
The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing
Nature Reviews Immunology (2014)
-
Footrace to clinic heats up for T-cell nuclear receptor inhibitors
Nature Biotechnology (2013)
-
The Th17 Pathway as a Therapeutic Target in Rheumatoid Arthritis and Other Autoimmune and Inflammatory Disorders
BioDrugs (2013)